DataMeds AI, Inc. (NASDAQ: MEDS) and Datavault AI Inc. (NASDAQ: DVLT) have amended their definitive agreement to significantly expand their technology licensing relationship beyond pharmaceutical distribution. The updated terms extend Datavault AI’s data monetization and real-world asset tokenization technologies into DataMeds AI’s EinsteinRx platform across all unencumbered commercial healthcare, healthspan, and wellness applications. This strategic expansion aims to transform healthcare data into a strategic asset for customer acquisition and commercial opportunities, leveraging a market where healthcare data represents approximately 30% of global data assets and grows at an estimated 36% annually.

The amendment changes the consideration structure for Datavault AI, which will now receive common shares representing approximately 19.9% of DataMeds AI’s common stock instead of preferred shares. Management stated this change was made to optimize the transaction for tax purposes. The share issuance remains subject to the satisfaction of closing conditions associated with broader multi-party business combinations involving Scilex Holdings and EOS Technology Holdings. These conditions include the acquisition of controlling interest in Tollo Health from HealthBridge Advisors and the acquisition of two QOLPOM intellectual property portfolios from EOS Technology Holdings.

Transaction Timeline and Strategic Rationale

The companies executed the amended agreement ahead of the final closing conditions to accelerate operational execution. This timing allows for the initiation of the private launch of the "Health Lives Here" app for NFL Alumni Health members at the 2026 Pro Football Hall of Fame Game in Canton, Ohio, on August 6, 2026. Gerald Commissiong, Interim Co-CEO of DataMeds AI, noted that the partnership provides confidence in transforming data into a foundation for future commercial opportunities rather than just operational insights.

Datavault AI CEO Nathaniel T. Bradley described the extension into commercial healthcare and wellness as a natural next step for patient-controlled data. He emphasized that DataMeds AI provides a focused path for individuals to have a say over how their medical information is transacted. The expanded relationship supports patient-controlled health data access and data-transaction models across pharmacy, medical, laboratory, and wearables settings.

Market Context and Financial Implications

The expansion targets a global health and wellness market exceeding $7 trillion. According to L.E.K. Consulting, healthcare data volume is projected to grow at a compound annual growth rate of 36% through 2025. The U.S. blockchain in healthcare market was valued at $7.13 billion in 2023 and is projected to reach $595.31 billion by 2032, at a CAGR of 63.5%, according to SNS Insider.

DataMeds AI, formerly Wellgistics Health, Inc., completed its corporate name change on July 21, 2026, with trading under the symbol 'MEDS' beginning on July 22, 2026. The company also announced a dividend of 50 Dream Bowl Meme Coin tokens for each share of DataMeds AI common stock owned as of the August 7, 2026 record date, subject to change at the company’s sole discretion. The value of the share issuance to Datavault AI is expected to be categorized as revenue upon the common share issuance.

What the Numbers Show

The shift from preferred to common stock consideration for Datavault AI signals a move toward aligning long-term equity value rather than fixed returns, optimizing for tax efficiency. With Datavault AI set to hold nearly 20% of DataMeds AI, the partnership creates a significant shared interest in the success of the expanded healthcare data monetization strategy. The reliance on closing conditions involving third-party acquisitions (Tollo Health and QOLPOM IP) introduces execution risk, but the accelerated timeline for the "Health Lives Here" app launch demonstrates operational momentum despite these dependencies.

DataMEDS AI, Inc. has officially commenced trading under the new stock symbol 'MEDS' on the Nasdaq Capital Market, effective Wednesday, July 22, 2026. This transition completes the corporate rebranding from the company's prior name, Wellgistics Health, Inc., which previously traded under the symbol 'WGRX'. The change reflects the company's strategic evolution as a Health IT leader integrating its artificial intelligence platform, EinsteinRx™, with its patented pharmacy smart contracts platform, PharmacyChain™.

The rebranding is designed to align the company's market identity with its core operations in healthcare technology. DataMEDS AI focuses on delivering a vertically aligned healthcare ecosystem that expands EinsteinRx™'s capabilities into medical, laboratory, and wearables fields. The company leverages a proprietary blockchain to tailor patient-specific solutions through its Health Lives Here app, initially targeting GLP-1-associated muscle loss and Long COVID patient bases.

Trading and Capitalization Details

The shift to the 'MEDS' ticker occurred on the Nasdaq Capital Market. Below are the key details regarding the company's current capitalization and trading status:

Strategic Focus and Market Outlook

DataMEDS AI intends to use its Health Lives Here infrastructure to consolidate electronic health data into a proprietary blockchain. This enables patients to participate in data transaction revenue, reduces data friction for providers, and allows for tailored clinical trial offerings. The company is also focused on completing a previously disclosed series of acquisition and licensing transactions.

Market data cited by the company indicates significant growth potential in its target sectors. The U.S. blockchain in healthcare market was valued at $7.13 billion in 2023 and is projected to reach $595.31 billion by 2032, representing a CAGR of 63.5%. Additionally, the GLP-1 receptor agonist market is expected to grow from $66 billion in 2025 to $185 billion in 2033, with a CAGR of 12.4%.

Gerald Commissiong, Interim Co-CEO of DataMEDS, stated that trading under the new symbol helps capture the attention of the Health IT investment community. He emphasized the company's mission to acquire and analyze data to optimize treatment decisions, including when to initiate, adjust, or discontinue prescription drug therapy.